Reuters logo
BRIEF-Janssen receives two FDA approvals for SIMPONI ARIA for treatment of active psoriatic arthritis
October 20, 2017 / 8:30 PM / a month ago

BRIEF-Janssen receives two FDA approvals for SIMPONI ARIA for treatment of active psoriatic arthritis

Oct 20 (Reuters) - Johnson & Johnson

* Janssen receives two U.S. FDA approvals for SIMPONI ARIA® (golimumab) for the treatment of adults with active psoriatic arthritis or active ankylosing spondylitis

* ‍Janssen Biotech says U.S. FDA approved SIMPONI ARIA for treatment of adults with active psoriatic arthritis or active ankylosing spondylitis​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below